AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01915433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wahls Paleo Plus
Description: The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
Study NCT01915433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wahls Diet
Description: The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
Study NCT01880372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid
Description: Same as Arm description
Study NCT03826511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tiszasüly hot mud-pack therapy
Description: Patients received Tiszasüly hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
Study NCT03826511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kolop mud-pack
Description: Patients received Kolop hot mud-packs (42 Celsius degree) for 30 minutes on 10 occasions for 2 weeks (10 working days) on the painful knee.
Study NCT04157465 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment strategy trial
Description: Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan>150 pg/ml, Galactomannan index>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures.
Study NCT04157465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment strategy trial
Description: Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include~1. Fungal Biomarkers positivity (Beta-D Glucan>150 pg/ml, Galactomannan index>1.0)~2. Mycological evidence of fungal infection on fungal cultures from a non-sterile site~3. Radiological evidence of fungal infection~4. Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis~Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures.
Study NCT03577574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: retrobulbar anesthesia
Description: 2% lidocaine 4ml injected into retrobulbar space
Study NCT04128904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Fertilisation with standard in vitro fertilisation (IVF). For details please see Project Description.
Study NCT04128904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: Fertilisation with intracytoplasmic sperm injection (ICSI). For details please see Project Description.
Study NCT04711174 — intervention group
Intervention type: BEHAVIORAL
Intervention: LMA removal
Description: the timing when conducting LMA removal
Study NCT03993574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self- management program
Description: The program sessions are either adapted from the Stanford Patient Education Research Center's program called the Chronic Disease Self-Management Program (CDSMP) or from a vision self-management program.~Despite which self-management program, the format for each session will include, review of educational materials (using the CDSMP book/article), discussion via a case vignette (which is always stroke related), and participation in an activity based on that session's topic. These group sessions will be 1.5 hours each week for 6 weeks
Study NCT03993574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: All stroke patients being discharged from the acute hospital receive the following care:~1. 1 follow-up call within 2 weeks by a nurse coordinator. The call involves checking if medications were able to be filled and how the person is feeling.~2. A stroke clinic appointment that is set to occur 90-days post discharge.~3. A list of their personal medications and generic educational materials. The educational materials are standard forms located in the Epic system. It is the nurses' responsibility to choose what forms to provide, however it is mandatory that stroke risk factor information is included.~4. Information on local support groups.~5. Referrals to start physical, occupational or speech therapy, if recommended by their physician.
Study NCT01000532 — intervention group
Intervention type: DEVICE
Intervention: SIELLO JT/T
Description: Implantation of SIELLO and BPPU pacemaker leads
Study NCT03577574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peribulbar anesthesia
Description: 2% lidocaine 4 to 8ml injected into peribulbar space
Study NCT03577574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two step anesthesia
Description: conjunctival cul-de-sac anesthetized with 0.5% proparacaine hydrochloride drops three times + 2% lidocaine 0.6 to 0.8ml subconjunctival injection
Study NCT01000532 — intervention group
Intervention type: DEVICE
Intervention: Pacemaker therapy
Description: Pacemaker therapy
Study NCT01000532 — intervention group
Intervention type: DEVICE
Intervention: BPPU JT/T
Description: Implantation of SIELLO and BPPU pacemaker leads
Study NCT02964754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scan for internal fixation
Description: In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
Study NCT02964754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional internal fixation
Description: In the control group, patients will undergo conventional internal fixation.
Study NCT03070769 — intervention group
Intervention type: PROCEDURE
Intervention: Venous blood collection for biomarkers measurements
Description: Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
Study NCT04453072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in interviews
Study NCT04453072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Receive iPhone with W8Loss2Go app
Study NCT04453072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04453072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scale Device
Description: Receive body scale and food scale
Study NCT04453072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone calls
Study NCT04453072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: Receive text message
Study NCT02380261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® Lid Wipes
Description: Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
Study NCT01844180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Study NCT01844180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-2952 Matching Placebo
Study NCT01805882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study NCT01805882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir
Study NCT01805882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9669
Study NCT01805882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9451
Study NCT03596437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultra High Frequency ultrasound system
Description: Agreement for carotid intima-media thickness in vascular Ehlers Danlos Syndrome and for triple signal identification in fibromuscular dysplasia will be assessed.
Study NCT01225822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
Study NCT01225822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
Study NCT01225822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
Study NCT01225822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
Study NCT01225822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048
Description: 300 mg q.d BIBR 1048 capsule for 5-10 treatment period
Study NCT00720174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV
Study NCT00720174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT00720174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02482636 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DTaP/IPV/Hib vaccine
Description: Given at 2, 3 and 4 months to Group 1 and 2
Study NCT02482636 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 13 valent Pneumococcal Conjugate Vaccine
Description: Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
Study NCT02482636 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Rotavirus vaccine
Description: Given at 2 and 3 months to Group 1 and 2
Study NCT02482636 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 4-component Meningococcal B vaccine
Description: Given at 2, 4 and 12 months to Group 1 and 2
Study NCT02482636 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningococcal C/Hib vaccine (MenC/Hib vaccine)
Description: Given at 12 months to Group1 and 2
Study NCT02482636 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Measles/Mumps/Rubella Vaccine (MMR vaccine)
Description: Given at 13 months to Groups 1 and 2
Study NCT03214289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Thirty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
Study NCT03585491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Latarjet Procedure
Description: Participants will undergo open or arthroscopic Latarjet procedure.
Study NCT03585491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bankart + Remplissage Procedure
Description: Participants will undergo arthroscopic stabilization.
Study NCT00624715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC
Description: * High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint~* Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint~* Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint
Study NCT00624715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
Study NCT02221245 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Biopsy via Ultrasound Endoscopy
Description: The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
Study NCT03862196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored text messages to improve retention in HIV care
Description: Trained counselors will deliver the text messages. After a block randomization, the trained counselor (a nurse) will send the first welcoming message to participants in the intervention arm. The nurse will send 2 tailored text messages per week. In addition 2 to 4 days before an appointment, the nurse will send a message reminder. In addition, the nurse will have bilateral communication with participants using text messages according to their needs. The participants of the intervention arm will interact with the nurse during 3 months with a semi-structured strategy, that is, with template text messages (predesigned) and open messages (for which the nurse will be trained). Three and six months after started the intervention the variables of interest will be assessed.
Study NCT03959592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutein, zeaxanthin and mesozeaxanthin
Description: The intervention will involve supplementation with the macular carotenoids (1 pill daily with a meal containing lutein, zeaxanthin, mesozeaxanthin) for six months, to determine the effects on visual performance in glaucoma patients.
Study NCT03959592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This intervention involves an inert pill (1 pill daily with a meal) that contains only sunflower oil, for six months.
Study NCT06158308 — intervention group
Intervention type: PROCEDURE
Intervention: Laproscopic Appendicectomy
Description: A type of surgery done without a large incision. Instead, from 1 to 3 tiny cuts are made. A long, thin tube called a laparoscope is put into one of the incisions. It has a tiny video camera and surgical tools.
Study NCT06158308 — intervention group
Intervention type: PROCEDURE
Intervention: Open Appendicectomy
Description: A cut or incision about 2 to 4 inches long is made in the lower right-hand side of your belly or abdomen. The appendix is taken out through the incision.
Study NCT02827942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg bid
Description: Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
Study NCT02827942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vonoprazan 20 mg bid
Description: Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
Study NCT02827942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 500 mg tid
Description: Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
Study NCT02827942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin 750 mg bid
Description: Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
Study NCT02827942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin 200 mg bid
Description: Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
Study NCT02827942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 250 mg bid
Description: Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
Study NCT02340520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Oral
Study NCT02340520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Oral
Study NCT00432510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study NCT01290822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiVP
Description: Biventricular pacing
Study NCT01290822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AAI Pacing
Description: Atrial pacing
Study NCT03716622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: bismuth-furazolidone-containing quadruple regimens
Study NCT03716622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: bismuth-clarithromycin-containing quadruple regimens
Study NCT01261143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BK-C-0701
Description: tablet, 8 weeks
Study NCT01261143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BK-C-0701
Description: tablet, 8 weeks
Study NCT01946581 — intervention group
Intervention type: PROCEDURE
Intervention: Cataract Surgery
Study NCT00089895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide (Integrilin)
Description: intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG \[coronary artery bypass graft\]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
Study NCT03348475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binge Focused Therapy (BFT) Intervention
Description: The intervention, Binge Focused Therapy, is a 3-session, 8-week, non-expert guided self-help program. Participants will attend sessions at Week 1, Week 2, and Week 8 at the Nova Scotia Health Authority Eating Disorder Clinic. Each session will be approximately 2 hours in length.
Study NCT01698879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylotarg
Description: Cohort 1 version 1.0. GO: 6mg/m\^2 (maximum 10 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 1.0 version 2.0: GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV days 1 to 7, to begin 4 hours after the administration of GO.~Cohort 2: G-CSF: 150 mcg/m\^2, SC, days 0 to 7. GO: 3 mg/m\^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m\^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine: 100 mg/m\^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO.
Study NCT01128101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
Study NCT03655912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red/green glasses
Description: The use of red/green glasses and electronic devices for two hours a day during 4 months.
Study NCT03655912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Tablet
Description: The use of eye patch on the fellow eye and electronic tablet for 2 hours a day during 4 months.
Study NCT03655912 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: The use of eye patch on the fellow eye and near vision activities for 2 hours a day during 4 months.
Study NCT02892422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.~From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)~Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study
Study NCT03740555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC042 single dose
Description: HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
Study NCT03740555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Placebo single ascending doses , Intravenous route Single dose, matching placebo
Study NCT03740555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC042 multiple ascending doses
Description: HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, anticipated doses: 300mg to 1200mg